Thapat Wannarong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thapat Wannarong has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
Grace Parraga
5 shared publications- John David Spence
Affiliation Stroke Prevention and Atherosclerosis Research Centre, Robarts Research Institute, Western University, London, Canada
4 shared publications Aaron Fenster
3 shared publications- Alberico Luigi Catapano
Department of Pharmacological and Biomolecular Sciences Università degli Studi di Milano Milan Italy
2 shared publications Albert Hofman
2 shared publicationsAlfonso Friera
2 shared publications
Latest Publications
- 25 November 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (10) , e214255
Natural History and Phenotypic Spectrum of Myofibrillar Myopathies and Myopathies Associated With MFM-Related Genes
Myofibrillar myopathy (MFM) is a pathologically defined but genetically heterogeneous myopathy; however, myofibrillar pathology may be absent in some patients with pathogenic variants in MFM-related genes. The natural history of MFM and myopathies associated with MFM-related genes remains poorly characterized. We retrospectively reviewed patients evaluated at Mayo Clinic (January 1993-March 2024) with either pathologically confirmed MFM or myopathies associated with MFM-related genes. Patients without genetic testing or skeletal muscular manifestations were excluded. Eighty patients were identified; 56 were genetically characterized (23 with DES, 10 with MYOT, 9 with LDB3, 2 with FLNC, 2 with BAG3, 2 with CRYAB, 1 with FHL1, and 7 others). Myofibrillar pathology was observed in 60 of 65 biopsied patients. The median age at symptom onset was 42.3 years (interquartile range [IQR] 20.2-57.0); 66 presented with muscular onset and 14 with cardiac onset. With a median disease duration of 13.1 years (IQR 8.1-24.0) from symptom onset to last visit, all patients had weakness, commonly distal-predominant (n = 34), followed by proximal-predominant (n = 24) and diffuse (n = 11) weakness. Dysphagia occurred in 16 patients, with 4 requiring feeding tubes. Peripheral neuropathy was found in 21 patients (13 with axonal large fiber neuropathy and 8 with small fiber neuropathy), mostly mild in severity. Gait aids were required in 46 patients (median 10.0 years after onset), and 17 became wheelchair-bound (median 19.0 years after onset). By age 60, 67% and 31% of patients with desminopathy required gait aids and were wheelchair-bound, respectively, compared with 12% and 0% of those with myotilinopathy and 25% and 0% of those with LDB3-related myopathy. Cardiac involvement (n = 31) and respiratory involvement (n = 33) were frequent, manifesting at a median of 7 and 9 years, respectively, after myopathy onset. Seven patients (2 with DES, 1 with ACTA1, 4 genetically uncharacterized) died, mainly due to cardiopulmonary complications. Patients with desminopathy exhibited earlier and higher rates of cardiac involvement (p < 0.001), more frequent respiratory involvement (p = 0.029), earlier gait aid dependence (p = 0.018) despite a similar age at ambulation loss (p = 0.418), lower prevalence of peripheral neuropathy (p = 0.022), and a similar mortality rate (p = 1.000). MFM and myopathies associated with MFM-related genes are clinically heterogeneous, with desminopathy showing earlier cardiac manifestations and gait aid requirement and more frequent cardiopulmonary involvement. Given the phenotypic variability, genetic diagnosis is crucial for patient management and prognosis.
- 25 November 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (10) , e214255
Natural History and Phenotypic Spectrum of Myofibrillar Myopathies and Myopathies Associated With MFM-Related Genes
Myofibrillar myopathy (MFM) is a pathologically defined but genetically heterogeneous myopathy; however, myofibrillar pathology may be absent in some patients with pathogenic variants in MFM-related genes. The natural history of MFM and myopathies associated with MFM-related genes remains poorly characterized. We retrospectively reviewed patients evaluated at Mayo Clinic (January 1993-March 2024) with either pathologically confirmed MFM or myopathies associated with MFM-related genes. Patients without genetic testing or skeletal muscular manifestations were excluded. Eighty patients were identified; 56 were genetically characterized (23 with DES, 10 with MYOT, 9 with LDB3, 2 with FLNC, 2 with BAG3, 2 with CRYAB, 1 with FHL1, and 7 others). Myofibrillar pathology was observed in 60 of 65 biopsied patients. The median age at symptom onset was 42.3 years (interquartile range [IQR] 20.2-57.0); 66 presented with muscular onset and 14 with cardiac onset. With a median disease duration of 13.1 years (IQR 8.1-24.0) from symptom onset to last visit, all patients had weakness, commonly distal-predominant (n = 34), followed by proximal-predominant (n = 24) and diffuse (n = 11) weakness. Dysphagia occurred in 16 patients, with 4 requiring feeding tubes. Peripheral neuropathy was found in 21 patients (13 with axonal large fiber neuropathy and 8 with small fiber neuropathy), mostly mild in severity. Gait aids were required in 46 patients (median 10.0 years after onset), and 17 became wheelchair-bound (median 19.0 years after onset). By age 60, 67% and 31% of patients with desminopathy required gait aids and were wheelchair-bound, respectively, compared with 12% and 0% of those with myotilinopathy and 25% and 0% of those with LDB3-related myopathy. Cardiac involvement (n = 31) and respiratory involvement (n = 33) were frequent, manifesting at a median of 7 and 9 years, respectively, after myopathy onset. Seven patients (2 with DES, 1 with ACTA1, 4 genetically uncharacterized) died, mainly due to cardiopulmonary complications. Patients with desminopathy exhibited earlier and higher rates of cardiac involvement (p < 0.001), more frequent respiratory involvement (p = 0.029), earlier gait aid dependence (p = 0.018) despite a similar age at ambulation loss (p = 0.418), lower prevalence of peripheral neuropathy (p = 0.022), and a similar mortality rate (p = 1.000). MFM and myopathies associated with MFM-related genes are clinically heterogeneous, with desminopathy showing earlier cardiac manifestations and gait aid requirement and more frequent cardiopulmonary involvement. Given the phenotypic variability, genetic diagnosis is crucial for patient management and prognosis.
- 2 July 2025
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 100 (8) , 1288-1289
Lymphoma Involving Skeletal Muscles: A Rare Mimic of Myositis
- 2 July 2025
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 100 (8) , 1288-1289
Lymphoma Involving Skeletal Muscles: A Rare Mimic of Myositis
- 6 April 2025
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 30 (2) , e70017
CIDP Treatment Outcomes Correlation With First Nerve Conduction Changes: Ascertainment of Initial and Long‐Term Responders
Background and Aims: Nerve conduction studies (NCS) are integral to diagnosing chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but their role in predicting treatment outcomes remains underexplored. This study evaluates NCS changes at first follow‐up (first NCS changes) as predictors of treatment success in CIDP, focusing on their correlation with clinical outcomes over time.Methods: Newly diagnosed CIDP patients meeting the 2021 EAN/PNS criteria were retrospectively evaluated. Baseline and first follow‐up NCS parameters were compared with clinical outcomes, assessed by the Neuropathy Impairment Score (NIS) and Inflammatory Neuropathy Cause and Treatment (INCAT) disability score. All patients received first‐line immunotherapy (intravenous immunoglobulin, corticosteroids, or plasma exchange).Results: Of 39 treated patients, 26 (66.7%) were responders based on improving NIS trends, while 13 (33.3%) were nonresponders. Responders showed significant improvements at the first follow‐up in fibular compound muscle action potential (CMAP) amplitude, ulnar CMAP amplitude, summated CMAP amplitudes, and fibular motor conduction velocity. Changes in fibular CMAP amplitude consistently correlated with NIS (R = −0.8 to −0.6, p ≤ 0.004) and INCAT disability score improvements (R = −0.6 to −0.3, p ≤ 0.032) across all follow‐up intervals up to 60 months. Ulnar and summated CMAP amplitude changes also correlated with clinical outcomes, though their associations were less sustained than those of fibular CMAP amplitude.Interpretation: The first change in fibular CMAP amplitude is a reliable biomarker for predicting CIDP treatment response, with ulnar and summated CMAP amplitudes as alternatives when the fibular response is absent. Our findings highlight the utility of first NCS changes in monitoring and predicting treatment outcomes in CIDP.
- 6 April 2025
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 30 (2) , e70017
CIDP Treatment Outcomes Correlation With First Nerve Conduction Changes: Ascertainment of Initial and Long‐Term Responders
Background and Aims: Nerve conduction studies (NCS) are integral to diagnosing chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but their role in predicting treatment outcomes remains underexplored. This study evaluates NCS changes at first follow‐up (first NCS changes) as predictors of treatment success in CIDP, focusing on their correlation with clinical outcomes over time.Methods: Newly diagnosed CIDP patients meeting the 2021 EAN/PNS criteria were retrospectively evaluated. Baseline and first follow‐up NCS parameters were compared with clinical outcomes, assessed by the Neuropathy Impairment Score (NIS) and Inflammatory Neuropathy Cause and Treatment (INCAT) disability score. All patients received first‐line immunotherapy (intravenous immunoglobulin, corticosteroids, or plasma exchange).Results: Of 39 treated patients, 26 (66.7%) were responders based on improving NIS trends, while 13 (33.3%) were nonresponders. Responders showed significant improvements at the first follow‐up in fibular compound muscle action potential (CMAP) amplitude, ulnar CMAP amplitude, summated CMAP amplitudes, and fibular motor conduction velocity. Changes in fibular CMAP amplitude consistently correlated with NIS (R = −0.8 to −0.6, p ≤ 0.004) and INCAT disability score improvements (R = −0.6 to −0.3, p ≤ 0.032) across all follow‐up intervals up to 60 months. Ulnar and summated CMAP amplitude changes also correlated with clinical outcomes, though their associations were less sustained than those of fibular CMAP amplitude.Interpretation: The first change in fibular CMAP amplitude is a reliable biomarker for predicting CIDP treatment response, with ulnar and summated CMAP amplitudes as alternatives when the fibular response is absent. Our findings highlight the utility of first NCS changes in monitoring and predicting treatment outcomes in CIDP.
- 13 August 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (3) , e209708
Clinical Reasoning: A 60-Year-Old Woman With Rapidly Progressive Muscle Weakness and Ophthalmoparesis
The clinical assessment of patients with proximal muscle weakness represents a frequent yet intricate challenge. We present the case of a 60-year-old woman who experienced a progressive, symmetrical weakness in proximal limbs and bulbar muscles over 6 months. Notable clinical findings included bilateral ophthalmoparesis; widespread muscle atrophy; and pronounced weakness in craniobulbar, cervical, and proximal muscles, more severe than in distal ones. We elucidate a methodical diagnostic approach, focusing on constructing a comprehensive differential diagnosis and identifying potential causes of proximal muscle weakness. Special emphasis is placed on exploring the etiologies in cases presenting with both progressive muscle weakness and ophthalmoparesis. We further describe the role of muscle biopsy results and their integration with genetic testing outcomes.
- 13 August 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (3) , e209708
Clinical Reasoning: A 60-Year-Old Woman With Rapidly Progressive Muscle Weakness and Ophthalmoparesis
The clinical assessment of patients with proximal muscle weakness represents a frequent yet intricate challenge. We present the case of a 60-year-old woman who experienced a progressive, symmetrical weakness in proximal limbs and bulbar muscles over 6 months. Notable clinical findings included bilateral ophthalmoparesis; widespread muscle atrophy; and pronounced weakness in craniobulbar, cervical, and proximal muscles, more severe than in distal ones. We elucidate a methodical diagnostic approach, focusing on constructing a comprehensive differential diagnosis and identifying potential causes of proximal muscle weakness. Special emphasis is placed on exploring the etiologies in cases presenting with both progressive muscle weakness and ophthalmoparesis. We further describe the role of muscle biopsy results and their integration with genetic testing outcomes.
- 11 October 2023
- Published by Wiley in Muscle & Nerve
- Vol. 69 (3) , 295-302
Neuromuscular ultrasound: Impact on diagnosis and management
Introduction/Aim: High‐resolution ultrasound (HRUS) is increasingly used in evaluating neuromuscular conditions. Its potential advantages include its ability to discern anatomic information and make specific etiological diagnoses. Although many studies have demonstrated HRUS effectiveness, especially in mononeuropathies, more information is needed to better determine how often and to what extent useful information is obtained; how it influences diagnosis, clinical decision‐making, and patient management; and how it is used with electrodiagnostic (EDx) studies.Methods: A retrospective cohort study was performed on patients referred for HRUS at a university laboratory during 2021. Demographic information, referral diagnoses, clinical information, HRUS findings, and follow‐up patient management were analyzed. For patients who had EDx, results were compared with HRUS. Determinations were made whether HRUS did or did not aid in the diagnosis. For patients in whom HRUS resulted in a diagnosis, determination was made whether it confirmed the diagnosis made clinically or by EDx but did not change management; added additional important information; and/or made a decisive impact on subsequent management.Results: Five hundred two patients were analyzed, most referred for mononeuropathy, brachial plexopathy, and polyneuropathy. HRUS was abnormal in 81.7% of patients. HRUS added additional useful information in 79.0% and was decisive in management in 62.7%. In patients who also had abnormal EDx, HRUS resulted in decisive management in 49.5%.Discussion: HRUS is an effective diagnostic tool that frequently adds localizing and structural information that is otherwise not obtainable by clinical and EDx evaluation. In a substantial number of patients selected for HRUS, it is decisive in guiding further management.
- 11 October 2023
- Published by Wiley in Muscle & Nerve
- Vol. 69 (3) , 295-302
Neuromuscular ultrasound: Impact on diagnosis and management
Introduction/Aim: High‐resolution ultrasound (HRUS) is increasingly used in evaluating neuromuscular conditions. Its potential advantages include its ability to discern anatomic information and make specific etiological diagnoses. Although many studies have demonstrated HRUS effectiveness, especially in mononeuropathies, more information is needed to better determine how often and to what extent useful information is obtained; how it influences diagnosis, clinical decision‐making, and patient management; and how it is used with electrodiagnostic (EDx) studies.Methods: A retrospective cohort study was performed on patients referred for HRUS at a university laboratory during 2021. Demographic information, referral diagnoses, clinical information, HRUS findings, and follow‐up patient management were analyzed. For patients who had EDx, results were compared with HRUS. Determinations were made whether HRUS did or did not aid in the diagnosis. For patients in whom HRUS resulted in a diagnosis, determination was made whether it confirmed the diagnosis made clinically or by EDx but did not change management; added additional important information; and/or made a decisive impact on subsequent management.Results: Five hundred two patients were analyzed, most referred for mononeuropathy, brachial plexopathy, and polyneuropathy. HRUS was abnormal in 81.7% of patients. HRUS added additional useful information in 79.0% and was decisive in management in 62.7%. In patients who also had abnormal EDx, HRUS resulted in decisive management in 49.5%.Discussion: HRUS is an effective diagnostic tool that frequently adds localizing and structural information that is otherwise not obtainable by clinical and EDx evaluation. In a substantial number of patients selected for HRUS, it is decisive in guiding further management.
- 17 August 2022
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 22 (9) , 785-789
Association between diabetic peripheral neuropathy and sarcopenia: A systematic review and meta‐analysis
Aim: The present study comprehensively investigated the relationship between diabetic peripheral neuropathy (DPN) and sarcopenia by identifying all eligible studies and summarizing their results.Methods: Records were identified through MEDLINE and EMBASE database searching from inception to March 9, 2022. We included all cross‐sectional studies investigating the association between DPN and sarcopenia among patients with diabetes. Data from eligible studies, including point estimates and standard errors, were pooled together using the generic inverse variance method.Results: Of 2989 retrieved articles, five studies met the inclusion criteria and were allowed for meta‐analysis. The pooled analysis found a significant association between DPN and sarcopenia with the pooled odds ratio of 1.62 (95% confidence interval: 1.30–2.02; I2 0%). The funnel plot was relatively symmetric and was not suggestive of the presence of publication bias.Conclusions: The current study discovered a significant association between DPN and sarcopenia in patients with diabetes. However, given summarized data from cross‐sectional studies, the temporality between DPN and sarcopenia could not be established. Geriatr Gerontol Int 2022; 22: 785–789.
- 17 August 2022
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 22 (9) , 785-789
Association between diabetic peripheral neuropathy and sarcopenia: A systematic review and meta‐analysis
Aim: The present study comprehensively investigated the relationship between diabetic peripheral neuropathy (DPN) and sarcopenia by identifying all eligible studies and summarizing their results.Methods: Records were identified through MEDLINE and EMBASE database searching from inception to March 9, 2022. We included all cross‐sectional studies investigating the association between DPN and sarcopenia among patients with diabetes. Data from eligible studies, including point estimates and standard errors, were pooled together using the generic inverse variance method.Results: Of 2989 retrieved articles, five studies met the inclusion criteria and were allowed for meta‐analysis. The pooled analysis found a significant association between DPN and sarcopenia with the pooled odds ratio of 1.62 (95% confidence interval: 1.30–2.02; I2 0%). The funnel plot was relatively symmetric and was not suggestive of the presence of publication bias.Conclusions: The current study discovered a significant association between DPN and sarcopenia in patients with diabetes. However, given summarized data from cross‐sectional studies, the temporality between DPN and sarcopenia could not be established. Geriatr Gerontol Int 2022; 22: 785–789.
- 25 October 2021
- Published by Wiley in Muscle & Nerve
- Vol. 65 (1) , 120-125
Statins and the risk of polyneuropathy: A systematic review and two meta‐analyses
Introduction/Aims: Previous studies have shown inconsistent data on the relationship between statin use and polyneuropathy (PN). The current systematic review and meta‐analyses were conducted to comprehensively investigate the risk of incident PN among statin‐users compared with non‐users by identifying all available studies and summarizing their results.Methods: A systematic review was conducted from MEDLINE and EMBASE databases from inception to October 31, 2020. We included cohort and case–control studies that compared the risk of incident PN between statin‐users and non‐users. Point estimates and standard errors from eligible studies were pooled together using the generic inverse variance method.Results: Of 4968 retrieved articles, 6 studies in non‐diabetic populations and 2 studies in diabetic populations fulfilled the inclusion criteria. Two meta‐analyses were performed. The pooled analyses did not find a statistically significant association between the use of statins and risk of incident PN with the pooled odds ratio of 1.24 (95% confidence interval [CI], 0.88–1.76; I274%) and 0.82 (95% CI, 0.56–1.21; I280%) in non‐diabetic and diabetic groups respectively.Discussion: No significant association between the use of statins and the risk of PN was observed in this systematic review and these two meta‐analyses. However, there was a high degree of heterogeneity of the meta‐analyses.
- 25 October 2021
- Published by Wiley in Muscle & Nerve
- Vol. 65 (1) , 120-125
Statins and the risk of polyneuropathy: A systematic review and two meta‐analyses
Introduction/Aims: Previous studies have shown inconsistent data on the relationship between statin use and polyneuropathy (PN). The current systematic review and meta‐analyses were conducted to comprehensively investigate the risk of incident PN among statin‐users compared with non‐users by identifying all available studies and summarizing their results.Methods: A systematic review was conducted from MEDLINE and EMBASE databases from inception to October 31, 2020. We included cohort and case–control studies that compared the risk of incident PN between statin‐users and non‐users. Point estimates and standard errors from eligible studies were pooled together using the generic inverse variance method.Results: Of 4968 retrieved articles, 6 studies in non‐diabetic populations and 2 studies in diabetic populations fulfilled the inclusion criteria. Two meta‐analyses were performed. The pooled analyses did not find a statistically significant association between the use of statins and risk of incident PN with the pooled odds ratio of 1.24 (95% confidence interval [CI], 0.88–1.76; I274%) and 0.82 (95% CI, 0.56–1.21; I280%) in non‐diabetic and diabetic groups respectively.Discussion: No significant association between the use of statins and the risk of PN was observed in this systematic review and these two meta‐analyses. However, there was a high degree of heterogeneity of the meta‐analyses.
- Open Access
- 20 September 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (9) , e0204633
Correction: Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk - Results from the PROG-IMT collaboration
[This corrects the article DOI: 10.1371/journal.pone.0191172.].
- 20 September 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (9) , e0204633
Open AccessCorrection: Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk - Results from the PROG-IMT collaboration
[This corrects the article DOI: 10.1371/journal.pone.0191172.].
- 11 September 2018
- Published by Springer Nature in Rheumatology International
- Vol. 38 (12) , 2279-2288
High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome
The objective of this study is to investigate the impact of skin sclerosis burden on an internal organ involvement over a 1-year period, as measured by time-adjusted accrual-modified Rodnan skin score (TA-mRSS), and to evaluate association between TA-mRSS patterns and laboratory tests in patients with systemic sclerosis (SSc). This prospective study was conducted at Siriraj Hospital (Bangkok, Thailand) during the November 2013–November 2016. SSc patients by ACR/EULAR 2013 or ACR 1980 criteria were eligible. TA-mRSS was classified as low, intermediate, or high, and then compared between groups. Correlation between the arithmetic mean of laboratory tests and TA-mRSS was assessed by multiple linear regression analysis. A total of 118 patients, with 81.4% women, median (IQR) age 49.8 (43.8, 55.1) years, disease duration from onset of non-Raynaud symptoms to first visit of 3.3 (1, 6.8) years, 78% dcSSc, and 75.3% anti-Scl-70 positivity, were analyzed. TA-mRSS over 1 year ranged from 0 to 37.44. The high skin sclerosis burden group had a median TA-mRSS > 7.26 (> 67th percentile). Patients with high TA-mRSS were dcSSc, high initial and average mRSS, and had tendon friction rub, digital ischemic complications, usual interstitial pneumonia, diastolic dysfunction, gastrointestinal dysmotility, and low serum albumin. In multiple linear regression analysis, the arithmetic mean of hemoglobin (B = − 1.007, 95% CI − 1.779 to − 0.236), erythrocyte sedimentation rate (B = − 0.078, 95% CI − 0.126 to − 0.029), serum glutamic oxaloacetic transaminase (B = 0.073, 95% CI 0.026–0.12), creatine phosphokinase (B = 0.012, 95% CI 0.003–0.021), and albumin (B = − 4.117, 95% CI − 6.958 to − 1.276) were associated with TA-mRSS. This study found a higher cumulative course of mRSS over a 1-year period to be significantly associated with severe internal organ involvement.
- 11 September 2018
- Published by Springer Nature in Rheumatology International
- Vol. 38 (12) , 2279-2288
High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome
The objective of this study is to investigate the impact of skin sclerosis burden on an internal organ involvement over a 1-year period, as measured by time-adjusted accrual-modified Rodnan skin score (TA-mRSS), and to evaluate association between TA-mRSS patterns and laboratory tests in patients with systemic sclerosis (SSc). This prospective study was conducted at Siriraj Hospital (Bangkok, Thailand) during the November 2013–November 2016. SSc patients by ACR/EULAR 2013 or ACR 1980 criteria were eligible. TA-mRSS was classified as low, intermediate, or high, and then compared between groups. Correlation between the arithmetic mean of laboratory tests and TA-mRSS was assessed by multiple linear regression analysis. A total of 118 patients, with 81.4% women, median (IQR) age 49.8 (43.8, 55.1) years, disease duration from onset of non-Raynaud symptoms to first visit of 3.3 (1, 6.8) years, 78% dcSSc, and 75.3% anti-Scl-70 positivity, were analyzed. TA-mRSS over 1 year ranged from 0 to 37.44. The high skin sclerosis burden group had a median TA-mRSS > 7.26 (> 67th percentile). Patients with high TA-mRSS were dcSSc, high initial and average mRSS, and had tendon friction rub, digital ischemic complications, usual interstitial pneumonia, diastolic dysfunction, gastrointestinal dysmotility, and low serum albumin. In multiple linear regression analysis, the arithmetic mean of hemoglobin (B = − 1.007, 95% CI − 1.779 to − 0.236), erythrocyte sedimentation rate (B = − 0.078, 95% CI − 0.126 to − 0.029), serum glutamic oxaloacetic transaminase (B = 0.073, 95% CI 0.026–0.12), creatine phosphokinase (B = 0.012, 95% CI 0.003–0.021), and albumin (B = − 4.117, 95% CI − 6.958 to − 1.276) were associated with TA-mRSS. This study found a higher cumulative course of mRSS over a 1-year period to be significantly associated with severe internal organ involvement.
- Open Access
- 12 April 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (4) , e0191172
Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk – Results from the PROG-IMT collaboration
Carotid intima media thickness (CIMT) predicts cardiovascular (CVD) events, but the predictive value of CIMT change is debated. We assessed the relation between CIMT change and events in individuals at high cardiovascular risk. From 31 cohorts with two CIMT scans (total n = 89070) on average 3.6 years apart and clinical follow-up, subcohorts were drawn: (A) individuals with at least 3 cardiovascular risk factors without previous CVD events, (B) individuals with carotid plaques without previous CVD events, and (C) individuals with previous CVD events. Cox regression models were fit to estimate the hazard ratio (HR) of the combined endpoint (myocardial infarction, stroke or vascular death) per standard deviation (SD) of CIMT change, adjusted for CVD risk factors. These HRs were pooled across studies. In groups A, B and C we observed 3483, 2845 and 1165 endpoint events, respectively. Average common CIMT was 0.79mm (SD 0.16mm), and annual common CIMT change was 0.01mm (SD 0.07mm), both in group A. The pooled HR per SD of annual common CIMT change (0.02 to 0.43mm) was 0.99 (95% confidence interval: 0.95–1.02) in group A, 0.98 (0.93–1.04) in group B, and 0.95 (0.89–1.04) in group C. The HR per SD of common CIMT (average of the first and the second CIMT scan, 0.09 to 0.75mm) was 1.15 (1.07–1.23) in group A, 1.13 (1.05–1.22) in group B, and 1.12 (1.05–1.20) in group C. We confirm that common CIMT is associated with future CVD events in individuals at high risk. CIMT change does not relate to future event risk in high-risk individuals.
- 12 April 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (4) , e0191172
Open AccessPredictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk – Results from the PROG-IMT collaboration
Carotid intima media thickness (CIMT) predicts cardiovascular (CVD) events, but the predictive value of CIMT change is debated. We assessed the relation between CIMT change and events in individuals at high cardiovascular risk. From 31 cohorts with two CIMT scans (total n = 89070) on average 3.6 years apart and clinical follow-up, subcohorts were drawn: (A) individuals with at least 3 cardiovascular risk factors without previous CVD events, (B) individuals with carotid plaques without previous CVD events, and (C) individuals with previous CVD events. Cox regression models were fit to estimate the hazard ratio (HR) of the combined endpoint (myocardial infarction, stroke or vascular death) per standard deviation (SD) of CIMT change, adjusted for CVD risk factors. These HRs were pooled across studies. In groups A, B and C we observed 3483, 2845 and 1165 endpoint events, respectively. Average common CIMT was 0.79mm (SD 0.16mm), and annual common CIMT change was 0.01mm (SD 0.07mm), both in group A. The pooled HR per SD of annual common CIMT change (0.02 to 0.43mm) was 0.99 (95% confidence interval: 0.95–1.02) in group A, 0.98 (0.93–1.04) in group B, and 0.95 (0.89–1.04) in group C. The HR per SD of common CIMT (average of the first and the second CIMT scan, 0.09 to 0.75mm) was 1.15 (1.07–1.23) in group A, 1.13 (1.05–1.22) in group B, and 1.12 (1.05–1.20) in group C. We confirm that common CIMT is associated with future CVD events in individuals at high risk. CIMT change does not relate to future event risk in high-risk individuals.